Lecture at outsourcing seminar, delivered by clinical research organisation, addresses fears of outsourcing clinical research
Danny Nasmyth-Miller, global project manager at mid-sized CRO Chiltern International, put the benefits of outsourcing under the spotlight recently.
He delivered the lecture - entitled 'Outsourcing - The Fear' - at the SMi Outsourcing of Drug Development international pharmaceutical industry conference held in London in September.
"The process of getting a drug successfully to market is far from easy, particularly at the stage of clinical trials," he explained.
"For every part of the complex clinical development process the pharmaceutical company must evaluate the time, logistics, expense and expertise that it can allocate".
The lecture also focused on the growth of the CRO as a business in general as more and more biotechnology and pharmaceutical companies opt to outsource their work to contract research organisations (CROs) like Chiltern International.
"There was a great deal of interest in the benefits offered by outsourcing and what the pharmaceutical industry can learn from other industries when it comes to this practice.
"There was general consensus that one of the most important ingredients in the success of a CRO is to manage the customer's fear of outsourcing and instil complete belief in them as a service provider.
"Simple to say, far harder to do".
This event was run by SMi Conferences and was designed to gather the views of those within pharmaceutical companies and CROs on outsourcing strategies and how outsourcing trends compare in the USA and in Europe.
The conference also explored global opportunities for CROs.
